Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up
出版年份 2014 全文链接
标题
Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume 74, Issue 10, Pages 1825-1829
出版商
BMJ
发表日期
2014-05-09
DOI
10.1136/annrheumdis-2014-205213
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response
- (2013) Leeyen Hsu et al. Expert Review of Clinical Immunology
- Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial
- (2012) In-Ho Song et al. ANNALS OF THE RHEUMATIC DISEASES
- Can we reduce the dosage of biologics in spondyloarthritis?
- (2012) Ignazio Olivieri et al. AUTOIMMUNITY REVIEWS
- Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis
- (2012) Suzanne Arends et al. CURRENT OPINION IN RHEUMATOLOGY
- Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria
- (2012) K. M. Fagerli et al. RHEUMATOLOGY
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease
- (2011) Victoria Navarro-Compán et al. CLINICAL RHEUMATOLOGY
- High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)
- (2011) F. Navarro-Sarabia et al. RHEUMATOLOGY
- Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
- (2010) P. Machado et al. ANNALS OF THE RHEUMATIC DISEASES
- Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis
- (2010) Jaejoon Lee et al. CLINICAL RHEUMATOLOGY
- Dealing with immunogenicity of biologicals: assessment and clinical relevance
- (2010) Gerrit J Wolbink et al. CURRENT OPINION IN RHEUMATOLOGY
- Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation
- (2009) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
- ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
- (2008) D van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis
- (2008) M K de Vries et al. ANNALS OF THE RHEUMATIC DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search